Morgan Stanley Reduces Stock Holdings in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

Morgan Stanley lowered its position in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 9.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 262,016 shares of the biopharmaceutical company’s stock after selling 27,327 shares during the quarter. Morgan Stanley owned about 0.57% of Bellicum Pharmaceuticals worth $445,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Nikko Asset Management Americas Inc. boosted its stake in Bellicum Pharmaceuticals by 98.5% during the second quarter. Nikko Asset Management Americas Inc. now owns 2,105,649 shares of the biopharmaceutical company’s stock worth $3,580,000 after buying an additional 1,044,811 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Bellicum Pharmaceuticals by 98.5% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,105,649 shares of the biopharmaceutical company’s stock worth $3,580,000 after purchasing an additional 1,044,811 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Bellicum Pharmaceuticals by 58.7% during the second quarter. Renaissance Technologies LLC now owns 1,564,959 shares of the biopharmaceutical company’s stock worth $2,660,000 after purchasing an additional 579,000 shares in the last quarter. Paloma Partners Management Co acquired a new stake in shares of Bellicum Pharmaceuticals during the second quarter worth about $307,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Bellicum Pharmaceuticals during the second quarter worth about $233,000. 52.87% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 8th. ValuEngine raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

In other Bellicum Pharmaceuticals news, CEO Richard A. Fair purchased 40,000 shares of Bellicum Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average price of $1.25 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief executive officer now owns 66,561 shares of the company’s stock, valued at $83,201.25. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have bought 68,000 shares of company stock worth $79,640 in the last three months. Corporate insiders own 2.64% of the company’s stock.

Shares of BLCM traded up $0.01 during mid-day trading on Tuesday, hitting $0.89. 2,275 shares of the company’s stock were exchanged, compared to its average volume of 873,448. The company has a market cap of $47.88 million, a price-to-earnings ratio of -0.36 and a beta of 1.48. Bellicum Pharmaceuticals Inc has a fifty-two week low of $0.72 and a fifty-two week high of $5.44. The company has a debt-to-equity ratio of 28.20, a quick ratio of 1.37 and a current ratio of 1.37. The stock’s 50-day moving average is $0.93 and its 200-day moving average is $1.61.

Bellicum Pharmaceuticals Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.

Recommended Story: What are the Benefits of Index Funds?

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit